Ignite Creation Date:
2024-05-05 @ 10:01 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002928
Status:
COMPLETED
Last Update Posted:
2013-06-26
First Post:
1999-11-01
Brief Title:
Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
A Phase II Trial of Paclitaxel Administered Weekly in Patients With Advanced Ovarian Cancer
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or progressive advanced epithelial ovarian cancer following previous paclitaxel
PURPOSE Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or progressive advanced epithelial ovarian cancer following previous paclitaxel
Detailed Description:
OBJECTIVES I Evaluate the activity of paclitaxel when administered on a weekly schedule to patients with advanced ovarian cancer who have failed paclitaxel on a 3 or 24 hour infusion schedule II Evaluate the toxic effects of paclitaxel when administered on a weekly schedule in this patient population III Correlate response with quality of life outcomes including symptom distress performance status and global quality of life
OUTLINE This is a single center open label study Paclitaxel is administered intravenously every week as a 1 hour infusion Patients receive prophylactic anti-allergy premedication prior to paclitaxel
PROJECTED ACCRUAL 25-30 patients accrued per year
OUTLINE This is a single center open label study Paclitaxel is administered intravenously every week as a 1 hour infusion Patients receive prophylactic anti-allergy premedication prior to paclitaxel
PROJECTED ACCRUAL 25-30 patients accrued per year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-G97-1139 | Registry Identifier | PDQ Physician Data Query | None |
| CDR0000065361 | REGISTRY | None | None |